Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


New Drug Discovery in Oncology: Faster, Cheaper and Better

In the next 3-7 years we're on track to develop personalized cancer therapeutics that have significantly improved efficacy and safety. With the near-precipitous drop in assay and sequencing costs, the emergence of immuno-oncology, the tipping point for big data, more adaptive clinical trial design, and modernization of the FDA, these improved therapeutics will also emerge at a faster speed and be offered at more competitive prices. In this session you will hear multiple viewpoints on this phenomenon from the panel including perspectives from medical oncology, pharma, regulatory and the patient advocate.


George W. Sledge, Jr., M.D., Professor, Division Chief, Stanford University Medical Center

Dr. George W. Sledge, Jr., M.D. is Professor and Chief of Medical Oncology at Stanford University Medical Center. Dr. Sledge served as a Ballve-Lantero Professor of Oncology of Medicine and Pathology of Indiana University School of Medicine. Read Full Bio

Gideon Michael Blumenthal, M.D., Clinical Team Leader, Lung and Head and Neck Cancers, FDA

Gideon Michael Blumenthal, MD is Clinical Team Leader for lung and head and neck cancers and Scientific Liaison for lung cancer in the Office of Hematology Oncology Products at the US FDA Center for Drug Evaluation and Research. Read Full Bio

August Salvado, M.D., VP of Early Development, Strategy and Innovation, Novartis

Dr. Salvado received his medical degree from Tufts University School of Medicine. He is Board Certified in Internal Medicine, Hematology and Medical Oncology. From 1975 to 1996, he worked at Walter Reed Army Institute of Research in Washington, D.C. Read Full Bio

Web Analytics